Ark Invest Swaps AMD Hardware for Tempus AI Precision Medicine

Cathie Wood’s Ark Invest is shifting its AI strategy away from semiconductor hardware and toward the application of artificial intelligence in healthcare. The firm has systematically reduced its exposure to Advanced Micro Devices (AMD) while increasing its position in Tempus AI.

According to data reported by Benzinga, Ark Invest offloaded nearly $48.4 million worth of AMD shares over the course of a single week. This aggressive sell-off included a single Friday where the firm sold nearly $21.1 million in AMD stock. Simultaneously, Ark Invest allocated approximately $7.7 million to purchase shares of Tempus AI (TEM), a company specializing in AI-powered precision medicine.

The Rise of Precision Medicine

This portfolio adjustment comes as Tempus AI demonstrates significant commercial momentum. The healthcare technology firm recently reported a 36.1% increase in first-quarter revenue, which reached $348.1 million. This growth was driven largely by the company's expansion in oncology diagnostics, positioning it as a key player in the intersection of clinical data and machine learning.

A Strategic Pivot in AI

The move signals a broader strategic pivot by Wood from traditional semiconductor hardware toward the monetization of AI-driven clinical data. While AMD provides the general-purpose computing power necessary for AI, Tempus AI represents the practical application of that power within the biotech and medical sectors. By rotating capital, Ark Invest is betting that the long-term value in the AI cycle will shift from the companies building the chips to those utilizing AI to solve complex biological problems.

Market Implications

This shift reflects a growing trend among disruptive tech investors to seek out "vertical AI"—applications tailored to specific industries—rather than relying solely on the "horizontal AI" provided by hardware manufacturers. As the market matures, the focus is moving toward how AI can generate tangible outcomes in patient care and drug discovery, rather than just the capacity to process data.

What to Watch

Investors will be monitoring whether Ark Invest continues to trim its semiconductor holdings in favor of biotech AI. While the firm has clearly increased its stake in Tempus AI, it remains to be seen if this is a temporary rebalancing or a permanent departure from its previous reliance on high-growth chipmakers to drive its AI thesis.